First Trust Advisors LP Has $27.80 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

First Trust Advisors LP lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 668,467 shares of the company's stock after purchasing an additional 31,645 shares during the quarter. First Trust Advisors LP owned about 0.17% of Moderna worth $27,795,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Forum Financial Management LP purchased a new position in Moderna in the 4th quarter worth about $225,000. Freedom Investment Management Inc. lifted its position in shares of Moderna by 50.3% in the 4th quarter. Freedom Investment Management Inc. now owns 8,071 shares of the company's stock valued at $336,000 after acquiring an additional 2,701 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in shares of Moderna by 24.4% in the 4th quarter. Canada Pension Plan Investment Board now owns 454,407 shares of the company's stock valued at $18,894,000 after acquiring an additional 89,235 shares in the last quarter. Altshuler Shaham Ltd grew its position in Moderna by 184.8% during the 4th quarter. Altshuler Shaham Ltd now owns 18,800 shares of the company's stock worth $782,000 after purchasing an additional 12,200 shares in the last quarter. Finally, United Capital Financial Advisors LLC raised its stake in Moderna by 48.8% during the 4th quarter. United Capital Financial Advisors LLC now owns 9,059 shares of the company's stock valued at $377,000 after purchasing an additional 2,972 shares during the period. Institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRNA. JPMorgan Chase & Co. dropped their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. Bank of America reduced their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Berenberg Bank boosted their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Citigroup began coverage on shares of Moderna in a research report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Finally, Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $58.70.

Moderna Price Performance

Shares of NASDAQ MRNA traded down $1.98 during trading hours on Thursday, hitting $26.56. 6,103,935 shares of the company's stock were exchanged, compared to its average volume of 7,384,457. The stock has a market capitalization of $10.27 billion, a price-to-earnings ratio of -2.87 and a beta of 2.23. The company's 50-day moving average price is $29.77 and its 200-day moving average price is $38.02. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.90) by $0.38. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm's revenue for the quarter was down 35.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.07) earnings per share. On average, research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.